- About Us
- Research & Pipeline
- Investor Centre
- Media Centre
Our CEO, Dr James Garner recently sat down with Morgans Senior Analyst Scott Power to provide a comprehensive update on our ongoing trials for our lead candidate, GDC-0084.
Professor Matt Dun was interviewed across leading broadcast and print media about his research into DIPG, a rare but aggressive form of childhood brain cancer.
Dr Matt Dun, a leading cancer researcher, discusses his research into Diffuse Intrinsic Pontine Glioma (DIPG) and GDC-0084.
Our CEO, Dr James Garner sat down with Boardroom Media in Sydney to discuss Kazia’s participation in the ground-breaking study with the US National Cancer Institute-backed Alliance for Clinical Trials in Oncology for the treatment of cancer that has spread to the brain.
Our CEO, Dr James Garner sat down with Karen Tan from Proactive Investors in Sydney to discuss the release of new safety and tolerability data from the company’s phase IIa trial of GDC-0084 in newly-diagnosed brain cancer patients.
This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of one of the deadliest women’s cancers worldwide.
Our CEO, Dr James Garner sat down with Karen Tan from Proactive Investors in Sydney to discuss the presentation of new data from the company’s Cantrixil trial in ovarian cancer at the American Association of Cancer Research (AACR) 2019 Annual Meeting on April 1.
Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting. AACR is one of the top-tier academic conferences worldwide and will be held from 29 March to 3 April at the Georgia World Congress Center in Atlanta, Georgia, USA.
Enter your email address to subscribe to our insights and receive notifications of new posts by email.
Required values are marked